Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec 14:5:122.
doi: 10.1186/1475-2875-5-122.

The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005

William J Collins  1 , Bryan Greenhouse, Philip J Rosenthal, Grant Dorsey
Affiliations

The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005

William J Collins et al. Malar J. .

Abstract

Background: The use of genotyping to distinguish recrudescent from new infections is currently recommended for all clinical antimalarial efficacy trials by the World Health Organization. However, genotyping-adjusted drug efficacy estimates may vary between trials due to the use of different genotyping methods and to the different settings in which these methods are applied.

Methods: A systematic review of all clinical antimalarial efficacy trials published from 1995-2005 was performed to characterize the use of genotyping, including the methods used and the effect of these methods on estimates of drug efficacy.

Results: In a multivariate analysis, the method of interpretation of genotyping results, the studied therapy, the location of the trial, and the duration of study follow-up all had statistically significant effects on the percent of genotyped outcomes classified as new infections.

Conclusion: Criteria for defining appropriate, standardized genotyping methods for use in different settings are needed to enable more accurate estimates of antimalarial drug efficacy and better comparison between trials. The advantages and disadvantages of different genotyping methods and their potential impact in various settings are discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Annual number of trials with and without genotyping by region. Total bar height represents all trials. White represents trials that used genotyping. Black represents trials that either did not use genotyping or did not have any episodes of recurrent parasitaemia to genotype.
See this image and copyright information in PMC

References

    1. World Malaria Report http://www.rbm.who.int/wmr2005/
    1. Susceptibility of Plasmodium falciparum to antimalarial drugs http://www.who.int/malaria/rbm/Attachment/20041108/SusceptibilityPlasmod...
    1. Guidelines for the Treatment of Malaria http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
    1. Farnert A, Arez AP, Babiker HA, Beck HP, Benito A, Bjorkman A, Bruce MC, Conway DJ, Day KP, Henning L, Mercereau-Puijalon O, Ranford-Cartwright LC, Rubio JM, Snounou G, Walliker D, Zwetyenga J, do Rosario VE. Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg. 2001;95:225–232. doi: 10.1016/S0035-9203(01)90175-0. - DOI - PubMed
    1. Slater M, Kiggundu M, Dokomajilar C, Kamya MR, Bakyaita N, Talisuna A, Rosenthal PJ, Dorsey G. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg. 2005;73:256–262. - PubMed

Publication types